Dapagliflozin Propanediol/Metformin Hydrochloride NCT07778719 Clini…

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Not Applicable

Clinical phase

Not yet recruiting

Recruitment status

84

Planned enrollment

2027-10-10

Primary-completion proxy

Executive view

NCT07778719 evaluates Dapagliflozin Propanediol/Metformin Hydrochloride in Diabetes Mellitus, Type 2. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is ΔIGF-1, assessed over 12 weeks.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07778719 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Diabetes Mellitus, Type 2 landscape. Drug & Asset MCP drug_fetch was queried for Dapagliflozin Propanediol/Metformin Hydrochloride, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07778719	Dapagliflozin Propanediol/Metformin Hydrochloride	Not Applicable / Not yet recruiting	Sponsor not reported	China	ΔIGF-1 12 weeks	2027-10-10
NCT07778524	Alpelisib	Phase 1 / Recruiting	Columbia University	United States	Correlation coefficient between clamp and ACT/MMTT Up to 17 hours after dosing alpelisib	2028-08-31
NCT07779343	Semaglutide (Novo Nordisk)	Not Applicable / Recruiting	Sponsor not reported	Algeria	Percentage of Participants Achieving ≥5% Weight Loss at Month 18 18 months follow-up	2028-01-23
NCT07775846	Finerenone	Phase 4 / Not yet recruiting	Zhongshan Hospital Fudan University	China	Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6 Baseline and Month 6	2029-02-28

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07778719 is a Not Applicable, not yet recruiting study with 84 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.

The primary endpoint is “ΔIGF-1” over “12 weeks.” The retrieved endpoint description is: The difference in the change value of serum IGF-1 levels (ΔIGF-1) from baseline to 3 months between the two groups..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 84 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

The protocol identifies Metformin Hydrochloride as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Diabetes Mellitus, Type 2. These records do not establish direct evidence for NCT07778719 unless the registration number matches.

A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhib…

Phase 2; n=39; Absolute Change in HbA1c(Least Squares Mean) = 0.16 percentage of glycosylated hemoglobin (95% Confidence Interval, -0.32 to 0.63); Absolute Change in HbA1c(Least Squares Mean) = -1.11 percentage of glycosylated hemoglobin (95% Confidence Interval, -1.6 to -0.62) Source: https://clinicaltrials.gov/ct2/show/results/NCT05232071

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweigh…

Phase 3; n=1613; Percent Change From Baseline in Body Weight(Least Squares Mean) = -2.21 percent change (Standard Error, 0.215); Percent Change From Baseline in Body Weight(Least Squares Mean) = -5.50 percent change (Standard Error, 0.356) Source: https://clinicaltrials.gov/ct2/show/results/NCT05872620

A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With…

Phase 2; n=1; Other (Not Including Serious) Adverse Events = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT07030868

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “Dapagliflozin Propanediol/Metformin Hydrochloride.” The report therefore avoids inferring modality, target or global development stage from the name alone.

No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Dapagliflozin Propanediol/Metformin Hydrochloride is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07778719
Protocol source: https://clinicaltrials.gov/study/NCT07778719
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

Dapagliflozin Propanediol/Metformin Hydrochloride in Diabetes Mellitus, Type 2 is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes ΔIGF-1 and 2027-10-10 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP

Dapagliflozin Propanediol/Metformin Hydrochloride in Diabetes Mellitus, Type 2: NCT07778719 Clinical Landscape Report 2026